Research programme: sensorineural hearing loss therapeutics - Oricula Therapeutics

Drug Profile

Research programme: sensorineural hearing loss therapeutics - Oricula Therapeutics

Alternative Names: ORC-0001; ORC-13661; OT-0001

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Washington
  • Developer Oricula Therapeutics
  • Class
  • Mechanism of Action Cell death inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Sensorineural hearing loss

Most Recent Events

  • 07 Feb 2018 Oricula holds composition of matter patents for OT 0001 and its analogues (Oricula Therapeutics website, February 2018)
  • 06 Feb 2018 ORC 13361 is still in preclinical development in USA
  • 05 Feb 2018 US FDA approves IND application of ORC 13361 to initiate clinical development in healthy volunteers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top